Internal Reference Number: FOI_7691
Date Request Received: 22/01/2024 00:00:00
Date Request Replied To: 23/02/2024 00:00:00
This response was sent via: By Email
Request Summary: GCA and HS
Request Category: Researcher
| Question Number 1: Could you please tell me how many patients were treated in the last 3 months for Hidradenitis Suppurativa (HS) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Bimekizumab • Certolizumab • Infliximab • Secukinumab • Ustekinumab | |
| Answer To Question 1: • Adalimumab - Humira <5 • Adalimumab Biosimilar 0 • Bimekizumab 0 • Certolizumab 0 • Infliximab 0 • Secukinumab 0 • Ustekinumab 0 | |
| Question Number 2: In the past 3 months, how many patients with a primary diagnosis of giant cell arteritis (ICD10 codes M31.5 or M31.6) were: • Admitted as an inpatient • Treated in A&E | |
| Answer To Question 2: Admitted as an inpatient = <= 5 Treated in A&E = <=5 | |
| Question Number 3: How many patients were treated by the rheumatology department in the past 3 months with the following: • Tocilizumab – for any disease • Tocilizumab for rheumatoid arthritis (RA) only • Tocilizumab for giant cell arteritis (GCA) only | |
| Answer To Question 3: • Tocilizumab – for any disease = 50 patients • Tocilizumab for rheumatoid arthritis (RA) only = 30 patients • Tocilizumab for giant cell arteritis (GCA) only = <5 patients | |
| Question Number 4: How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab? | |
| Answer To Question 4: 0 - the drug is given by Rheumatology. | |
| Question Number 5: How many patients were treated in A&E in the past 3 months (for any disease) with Tocilizumab? | |
| Answer To Question 5: 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
